CD20
15 drugs OncologyCNS
6
approved indications
15
Approved Drugs
8
Companies
23
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (8 companies)
✓ All 15 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (23 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 7 drugs
Novartis 2 drugs
CELLTRION INC 1 drug
By Therapeutic Area
Oncology 9 drugs
Other 5 drugs
Drugs by Company PRO
By Therapeutic Area
Oncology 9 drugs
TRUXIMA, RITUXAN, RUXIENCE, RIABNI +5 more
Other 5 drugs
ARZERRA, KESIMPTA, BRIUMVI, OCREVUS +1 more
CNS 1 drugs
OCREVUS ZUNOVO
Indications Treated
Clinically isolated syndromeRelapsing-remitting multiple sclerosisActive secondary progressive multiple sclerosisPreviously untreated chronic lymphocytic leukemia in combination with chlorambucil for patients for whom fludarabine-based therapy is considered inappropriateRelapsed chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamideExtended treatment of recurrent or progressive chronic lymphocytic leukemia in patients with complete or partial response after at least two lines of therapyChronic lymphocytic leukemia refractory to fludarabine and alemtuzumabNon-Hodgkin's LymphomaChronic Lymphocytic LeukemiaRheumatoid ArthritisGranulomatosis with PolyangiitisMicroscopic PolyangiitisPemphigus VulgarisMultiple SclerosisDiffuse Large B-Cell LymphomaFollicular LymphomaHigh-Grade B-Cell LymphomaBurkitt LymphomaMature B-Cell Acute LeukemiaDiffuse Large B-cell LymphomaLupus NephritisRelapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease)Primary progressive multiple sclerosis
All Drugs Targeting CD20
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TRUXIMA Top | CELLTRION INC | 2018 | 6 | Oncology |
| RITUXAN Top | Roche | 1997 | 6 | Oncology |
| RUXIENCE Top | Pfizer | 2019 | 6 | Oncology |
| RIABNI | Amgen | 2020 | 6 | Oncology |
| ARZERRA | Novartis | 2009 | 4 | |
| KESIMPTA | Novartis | 2009 | 3 | |
| EPKINLY | GENMAB US, INC. | 2023 | 3 | Oncology |
| BRIUMVI | TG THERAPEUTICS, INC | 2022 | 3 | |
| RITUXAN HYCELA | Roche | 2017 | 3 | Oncology |
| GAZYVA | Roche | 2013 | 3 | Oncology |
| COLUMVI | Roche | 2023 | 2 | Oncology |
| OCREVUS | Roche | 2017 | 2 | |
| OCREVUS ZUNOVO | Roche | 2024 | 1 | CNS |
| ZEVALIN | SPECTRUM PHARMS | 2002 | 1 | |
| LUNSUMIO | Roche | 2022 | 1 | Oncology |